An Open Therapeutic Observational Evaluation of the Efficacy and Safety Profile of Lantus in Everyday Medical Practice in Type 2 Diabetes Mellitus Patients, Who Start Receiving Lantus - Treated With Any Other Insulin, With A1c greater than 7%.
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LAPAS
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2009 Actual end date changed from Jun 2008 to May 2008 as reported by ClinicalTrials.gov.
- 26 May 2009 Primary outcome amended as reported by ClinicalTrials.gov.